Qian Nie

Qian Nie

Auto-generated profile, based on publicly available information

Qian Nie

Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, Minnesota, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2017 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
QNQ Nie
Q Nie
SSS Shrestha
S Shrestha
ETEe Tapper
Ee Tapper
CTCs Trogstad‐Isaacson
Cs Trogstad‐Isaacson
KBKj Bouchonville
Kj Bouchonville
RDRb Diasio
Rb Diasio

11 October 2016 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Closed access
PDF file
TET Elraiyah
T Elraiyah
CJCr Jerde
Cr Jerde
SSS Shrestha
S Shrestha
RWR Wu
R Wu
QNQ Nie
Q Nie
RDRb Diasio
Rb Diasio

31 October 2016 in Cancer Research
Verified
Journal Article
Open access
PDF file
RWRentian Wu
Rentian Wu
QNQian Nie
Qian Nie
ETErin E. Tapper
Erin E. Tapper
CJCalvin R. Jerde
Calvin R. Jerde
GDGarrett S. Dunlap
Garrett S. Dunlap
RDRobert B. Diasio
Robert B. Diasio
The antimetabolite 5-fluorouracil (5-FU) is one of the most widely used chemotherapy drugs. Dihydropyrimidine dehydrogenase (DPD) is a major determinant of 5-FU response and toxicity. Although DPYD variants may affect 5-FU metabolism, they do not completely explain the reported variability in DPD function or the resultant differences in treatment response. Here, we report that H3K27 trimethylation (H3K27me3) at the DPYD promoter regulated by Ezh2 and UTX suppresses DPYD expression by inhibiting transcription factor PU.1 binding, leading to increased resistance to 5-FU. Enrichment of H3K27me3 at the DPYD promoter was negatively correlated with both DPYD expression and DPD enzyme activity in peripheral blood specimens from healthy volunteers. Lastly, tumor expression data suggest that DPYD repression by Ezh2 predicts poor survival in 5-FU–treated cancers. Collectively, the findings of the present article suggest that a previously uncharacterized mechanism regulates DPD expression and may contribute to tumor resistance to 5-FU. Cancer Res; 76(21); 6362–73. ©2016 AACR.